RIBOXIN®

Dosage and Administration

This drug is produced in several dosage forms.

  1. Riboxin tablets are recommended to be taken 15-30 minutes before meals without chewing and with plenty of water. The standard scheme is 0.6–2.4 g of the drug per day. The course begins with a 0.6-0.8 g dosage. The daily dose must be divided into several intakes. If there are no adverse manifestations, the dose is increased to the average daily one. The therapeutic course varies from 1 to 3 months.
  2. Riboxin solution in ampoules is used when it is necessary to immediately inject the drug into the bloodstream. An injection solution is administered by droppers, bypassing the gastrointestinal tract, by stream or drip infusion. The length of the course is determined individually for each patient.

Riboxin must be administered after a consultation with a doctor. The choice of the dose and form of the drug depends on the disease and the patient's condition.

Side Effects

Clinical studies have shown that Riboxin has good tolerance. Undesirable manifestations include following symptoms:

  • Increased heart rate (tachycardia);
  • Hypotension (low blood pressure), accompanied by headache, dizziness, short breathing, nausea, vomiting;
  • Allergic reactions (various rashes, skin itching, redness of the skin).

When the drug is canceled, unpleasant symptoms tend to disappear.

The drug is prescribed with caution in case of renal failure and diabetes (1 tablet contains 0.00641 XE).

Contraindications:

The use of the drug is contraindicated in the following conditions: intolerance to Riboxin components; age up to 18 years old; joint disease caused by the pre-existing deposition of uric acid salts (gouty arthritis); increased uric acid levels in the blood (hyperuricemia); renal failure.

Analogs:

Pharmacists have created Riboxin analogues with the same metabolic effect and the same active component (inosine). They are Cytoflavin and Ribonozin. However, the replacement of Riboxin with its structural analogues, as a rule, is only practical in case of individual intolerance to the drug excipients. A significant advantage of Riboxin over its analogues is its price.

Note:

Riboxin in sports is often used by bodybuilders and athletes, especially those who do not take steroids and are against doping. It is used as a dietary supplement to keep the body fit, to build and develop muscle and its definition. According to its pharmacological properties, the drug is similar to most anabolic steroids. It's said to accelerate cellular metabolism, increase protein synthesis in muscle tissue and work to restore muscles. In addition, it helps the heart to work in condition of oxygen starvation which is common for patients with coronary heart disease. It contributes to the blood circulation improvement, and to better nutrition of the heart muscle.

Nutritionists sometimes prescribe Riboxin for weight loss. In this case, the desired effect may only be obtained if the drug is accompanied by a comprehensive diet and weightlifting exercise.

Riboxin is a purine derivative. It can be considered a nucleoside that is a substance naturally found in the cells of the body and is the precursor of adenosine triphosphate - ATP.

The main component of the drug is inosine. It is part of a group of drugs with a metabolic effect. Once in the heart muscle, this substance is known to stabilize and activate the energy balance. It may normalize metabolism in the myocardium. Riboxin takes part in glucose metabolism, improves digestion, and helps in liver and kidney diseases therapy including renal ischemia.

Inosine demonstrates the possibility to enhance heart contractions and relaxe myocardial fibers during diastole, after which the stroke volume of the blood becomes larger. It is stated to improve blood circulation in coronary vessels and improve the condition of areas with reduced blood supply. It stimulates the restoration of anemic tissues, reduces platelet plug, and may restore myocardial tissue and gastrointestinal mucosa.

Riboxin can also normalize tissue respiration, demonstrating an antihypoxic effect and accelerating the utilization of oxygen circulating in the body. It may also reduce the deficiency of oxygen of internal organs, associated with the lack of the latter. It activates metabolism in hypoxia, and increases resistance to oxygen deficiency. Riboxin shows an antiarrhythmic effect, normalizing heart contractions.

The properties of Riboxin determine its most important contribution which is considered to be the treatment of cardiovascular diseases. Riboxin is prescribed for adults with: heart rhythm disturbances; severe forms of ischemia; myocardial infarction; arrhythmias caused by excess doses of glycosides; myocarditis; damage to the coronary arteries that feed the heart; "pulmonary" heart (increase or expansion of its sections); individual forms of glaucoma; congenital or acquired heart abnormalities; myocardial dystrophy caused by physical overload or endocrine pathology; disorders of the liver, etc.

*The drug is also of wide use among athletes, since its use is asserted to enhance the restoration of carbohydrate, protein and fat metabolism, which increases the body's defenses and the effectiveness of training.

  1. Komarov FI et al (1979). Experience in the use of the Soviet drug riboxin in therapeutic practice. https://www.ncbi.nlm.nih.gov/pubmed/531611
  2. Kukes VG et al (1983). Mechanism of the effect of riboxin. https://www.ncbi.nlm.nih.gov/pubmed/6857353
  3. Bondarenko IP (1983). Effect of riboxin on hemodynamics and microcirculation in patients with chronic ischemic heart disease. https://www.ncbi.nlm.nih.gov/pubmed/6868490
  4. Dorofeev GI et al (1984). Riboxin treatment of peptic ulcer patients. https://www.ncbi.nlm.nih.gov/pubmed/6719882
  5. Borovkova MS, Neĭko EM (1988). Use of riboxin in the complex treatment of patients with acute pneumonia. https://www.ncbi.nlm.nih.gov/pubmed/3400234
  6. Frantsuzova SB et al (1989). Pharmacodynamics of riboxin (inosine). https://www.ncbi.nlm.nih.gov/pubmed/2651150
  7. Aleksandrova AE et al (1989). The results of the use of riboxin in the combined treatment of patients with pulmonary tuberculosis. https://www.ncbi.nlm.nih.gov/pubmed/2511573
  8. Rudyk BI et al (1989). The effect of riboxin on lipid peroxidation in patients with acute myocardial infarct. https://www.ncbi.nlm.nih.gov/pubmed/2588512
  9. Shulipa IV et al (1990). The riboxin treatment of workers in the electron vacuum tube industry suffering from dermatoses. https://www.ncbi.nlm.nih.gov/pubmed/2142361
  10. Skakun NP, Slivka IuI (1992). The correction of the hepatotoxicity of antitubercular preparations with tocopherol acetate and riboxin. https://www.ncbi.nlm.nih.gov/pubmed/1458166
  11. Vlasov NN et al (1992). The possible carcinogenic properties of riboxin (inosie F). https://www.ncbi.nlm.nih.gov/pubmed/1300804
  12. Laskova IL, Uteshev BS (1992). The immunomodulating action of riboxin during physical loading. https://www.ncbi.nlm.nih.gov/pubmed/1305453
  13. Beketov AI et al (2000). Comparative characteristics of cerebrovascular protective effects of mildronate, riboxine, and their combination during modeling of cerebral hemodynamics disturbance. https://www.ncbi.nlm.nih.gov/pubmed/11202503
  14. Konoplia NA et al (2002). Effects of riboxin, essentiale, and phylloquinone on the immunomodulating and antioxidant effect of laser and magneto-laser irradiation in liver toxicosis induced by gentamycin. https://www.ncbi.nlm.nih.gov/pubmed/12025789
  15. Lazareva GA, Brovkina IL (2006). The protective action of essentiale, riboxin, and elkar against hemotoxic anemia. https://www.ncbi.nlm.nih.gov/pubmed/16845941
  16. Gudkov SV et al (2007). Guanosine and inosine (riboxin) eliminate the long-lived protein radicals induced X-ray radiation. https://www.ncbi.nlm.nih.gov/pubmed/17546951
  17. Ekusheva EV (2017). Modern technologies and prospects of rehabilitation of patients after ischemic stroke. https://www.ncbi.nlm.nih.gov/pubmed/29376998


Type: Unknown Type




CUSTOMERS WHO BOUGHT THIS PRODUCT ALSO BOUGHT